Outcome of CBV (Carmustine, Cyclophosphamide, Etoposide) Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma: A Retrospective Study from a Tertiary Cancer Center in South India

Abstract

Introduction In autologous stem cell transplant (ASCT) for lymphomas, no standard conditioning regimen has been defined so far. Thus, the choice is guided by the center's familiarity and experience with a particular regimen.

Objective To determine the response, toxicity, and survival outcomes in lymphoma patients who underwent ASCT with CBV (cyclophosphamide, carmustine, and etoposide) conditioning regimen.

Materials and Methods Between January 2013 and May 2019, 45 consecutive lymphoma patients who had ASCT with CBV conditioning regimen were included in this retrospective study. CBV consisted of cyclophosphamide (1.5 g/m²/day × 4 days), carmustine (300 mg/m² × 1 day), and etoposide (125 mg/m² twice daily × 3 days). Baseline characteristics, pre transplant response, apheresis, post-transplant toxicities, post-transplant response, and survival outcomes were collected. Endpoints were toxicity, response, event-free survival (EFS), and overall survival (OS).

Results The median age was 30 (range: 6–64) years. Diagnosis was Hodgkin lymphoma (HL) in 26 (58%) and non-Hodgkin lymphoma (NHL) in 19 (42%). Forty-three patients (95%) had chemosensitive disease; 22(49%) in CR, and 21 (46%) in PR. The median CD34 was 2.95 × 10⁶/kg (range: 0.9–9.56). The median time to neutrophil engraftment was 11 days (9–23) and 13 (8–36) days for platelets. All patients had febrile neutropenia, clinically and/or microbiologically documented infection was seen in 75% of patients. The most common grade 3/4 toxicities were mucositis (n = 4, 9%), diarrhea (n = 4, 9%), and nausea/vomiting (n = 2, 4%). The average days of hospitalization was 18 (range: 10–37). Day 100 mortality was 6.6% (n = 3). The median follow-up was 44.8 months. The median EFS for the entire cohort was 23.8 months; for HL, the median EFS was not reached, and for NHL, it was 7.97 months (95% confidence interval [CI]: 1.57–14.37). The median OS for the entire cohort and for HL was not reached; for NHL, it was 24.3 months (95% CI: 0.56–48.11).

Conclusion CBV conditioning regimen was well tolerated with low grade 3/4 toxicities and efficacy comparable to literature data.

Keywords

CBV conditioning regimen - autologous stem cell transplant - Hodgkin lymphoma - non-Hodgkin lymphoma

• References

• 1 Philip T, Biron P. High-dose chemotherapy and autologous bone marrow transplantation in diffuse intermediate- and high-grade non-Hodgkin lymphoma. Crit Rev Oncol Hematol 2002; 41 (02) 213-223
• 2 Sureda A, Bader P, Cesaro S. et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015; 50 (08) 1037-1056
• 3 Salar A, Sierra J, Gandarillas M. et al; GEL/TAMO Spanish Cooperative Group. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant 2001; 27 (04) 405-412
• 4 Mounier N, Gisselbrecht C. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 1998; 9 (Suppl. 01) S15-S21
• 5 Philip T, Guglielmi C, Hagenbeek A. et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333 (23) 1540-1545
• 6 Isidori A, Christofides A, Visani G. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. Leuk Lymphoma 2016; 57 (11) 2499-2509
• 7 Philip T, Chauvin F, Bron D. et al. PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients). Ann Oncol 1991; 2 (Suppl. 01) 57-64
• 8 Rajamanickam D, Gokarn A, Gupta A. et al. LACE - an effective conditioning regimen for lymphoma patients undergoing autologous transplant- analysis of outcomes and prognostic factors. J Cancer Res Ther 2018; 14 (05) 926-933
• 9 Galieni P, Troiani E, Bigazzi C. et al. Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2018; 53 (01) 91-93
• 10 Chen Y-B, Lane AA, Logan B. et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015; 21 (06) 1046-1053
• 11 Arranz R, Tomás JF, Gil-Fernández JJ. et al. Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant. Bone Marrow Transplant 1998; 21 (08) 779-786
• 12 Puig N, de la Rubia J, Remigia MJ. et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 2006; 47 (08) 1488-1494
• 13 Khattry N, Gupta A, Jain R. et al. LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy. Int J Hematol 2016; 103 (03) 292-298
• 14 Shi Y, Liu P, Zhou S. et al. Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: efficacy and toxicity. Asia Pac J Clin Oncol 2017; 13 (05) e423-e429
• 15 Sharma A, Kayal S, Iqbal S, Malik PS, Raina V. Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. Springerplus 2013; 2: 489
• 16 Harris RE, Termuhlen AM, Smith LM. et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. Biol Blood Marrow Transplant 2011; 17 (02) 249-258
• 17 Colby C, McAfee SL, Finkelstein DM, Spitzer TR. Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998; 21 (10) 1005-1010
• 18 de Azevedo AM, Nucci M, Maiolino A. et al. A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 2002; 29 (09) 745-751
• 19 Valcárcel D, Sureda A. Graft failure. In: Carreras E, Dufour C, Mohty M, Kröger N. eds. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed.. Springer; 2019: 307-313
• 20 Murray S. Engraftment. In: Maziarz RT, Slater SS. eds. Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care. Springer International Publishing; 2015: 161-165
• 21 Maiolino A, Biasoli I, Lima J, Portugal AC, Pulcheri W, Nucci M. Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria. Bone Marrow Transplant 2003; 31 (05) 393-397
• 22 Bearman SI, Appelbaum FR, Buckner CD. et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6 (10) 1562-1568
• 23 Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. Accessed October 18, 2021 at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
• 24 Dos Santos KB, Costa LJM, Bettarello G. et al. LEAM versus CBV for conditioning in autologous hematopoietic stem cell transplantation for lymphoma. Bone Marrow Transplant 2019; 54 (04) 625-628
• 25 Bishop MR, Dean RM, Steinberg SM. et al. Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Cancer 2010; 116 (04) 852-862
• 26 Nieto Y, Popat U, Anderlini P. et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 2013; 19 (03) 410-417